Last reviewed · How we verify
Use of bromfenac 0.09% to reduce intravitreal injection pain — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Use of bromfenac 0.09% to reduce intravitreal injection pain (Use of bromfenac 0.09% to reduce intravitreal injection pain) — Wills Eye.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Use of bromfenac 0.09% to reduce intravitreal injection pain TARGET | Use of bromfenac 0.09% to reduce intravitreal injection pain | Wills Eye | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Use of bromfenac 0.09% to reduce intravitreal injection pain CI watch — RSS
- Use of bromfenac 0.09% to reduce intravitreal injection pain CI watch — Atom
- Use of bromfenac 0.09% to reduce intravitreal injection pain CI watch — JSON
- Use of bromfenac 0.09% to reduce intravitreal injection pain alone — RSS
Cite this brief
Drug Landscape (2026). Use of bromfenac 0.09% to reduce intravitreal injection pain — Competitive Intelligence Brief. https://druglandscape.com/ci/use-of-bromfenac-0-09-to-reduce-intravitreal-injection-pain. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab